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Abstract 
To reduce lithium-induced nephrogenic diabetes insipidus (lithium-NDI), bipolar patients are 
treated with thiazide/amiloride, which are thought to induce antidiuresis by a compensatory 
increased pro-urine uptake in proximal tubules. However, as thiazides induced an antidiuresis 
in lithium-NDI mice lacking the sodium-chloride co-transporter and alkalinized their urine, 
this concept was challenged and suggested that inhibition of carbonic anhydrases (CA) 
conferred the beneficial thiazide effect. Therefore, we here tested the effect of the CA-specific 
blocker acetazolamide in lithium-NDI. 
In collecting duct (mpkCCD) cells, acetazolamide reduced the cellular lithium content and 
attenuated lithium-induced downregulation of AQP2 through a mechanism different from 
amiloride. Treatment of lithium-NDI mice with acetazolamide or thiazide/amiloride revealed 
a similar antidiuresis, increased urine osmolality and AQP2 abundance. The reduced inulin 
clearance and cortical NHE3 expression demonstrated that the antidiuresis with acetazolamide 
was partially due to a tubular-glomerular feedback (TGF) response and reduced GFR. The 
TGF response and/or direct effect on collecting duct principal or intercalated cells may 
underlie the reduced urinary PGE2 levels with acetazolamide, thereby contributing to the 
attenuated lithium-NDI. Thiazide/amiloride-treated mice showed hyponatremia, 
hyperkalemia, hypercalcaemia, metabolic acidosis and increased serum lithium 
concentrations; side effects also observed in patients, but not seen in acetazolamide-treated 
mice.  
In conclusion, we have shown that CAs activity contributes to lithium-NDI development, that 
acetazolamide attenuates lithium-induced NDI by inducing a TGF response and through a 
direct action on collecting duct cells, and that acetazolamide attenuates lithium-NDI 
development similar to thiazide/amiloride but with less side effects. 
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Introduction  
Lithium is the drug of choice for the treatment of bipolar disorders and is also regularly used 
to treat schizoaffective disorders and depression. Lithium is a frequently prescribed drug as it 
is provided to 0.1% of the western population. Unfortunately, in 2-85% of patients, and 
depending on age, lithium usage leads to nephrogenic diabetes insipidus (Li-NDI), a disorder 
characterized by an impaired response of the kidney to vasopressin (AVP) leading to polyuria 
and polydipsia1-3. Patients with Li-NDI are at risk for dehydration-induced lithium toxicity, 
and prolonged lithium treatment might lead to cyst formation and end stage renal disease4. 
However, cessation of lithium therapy is not an option for most patients with NDI, because 
bipolar disorder symptoms have a larger impact on the patient’s quality of life. 
From studies in rats, it became clear that Li-NDI develops in two stages. At short term (10 
days), Li-NDI coincides with downregulation of aquaporin-2 (AQP2) water channels, which 
is due to a reduced AQP2 transcription5-7. Despite an increased proliferation of the AQP2-
expressing principal cells of the collecting duct, long-term lithium treatment (4 weeks) also 
results in a severe loss of AQP2-expressing principal cells, which might be attributed to a 
lithium-induced G2/M phase cell cycle arrest8, 9. This principal cell loss is ‘compensated’ by 
an increased number of α-intercalated cells, which are involved in acid secretion8. 
To reduce polyuria in patients receiving lithium, a low-sodium diet together with thiazide and 
amiloride diuretics is prescribed10. Amiloride acts on the principal cell epithelial sodium 
channel (ENaC) and we and others found that amiloride blocks principal cell lithium entry 
through ENaC, thereby attenuating polyuria in rodents and humans11-13. Thiazides are known 
to block sodium and chloride reabsorption via the NaCl co-transporter (NCC) in the renal 
distal convoluted tubule and the antidiuretic effect has been ascribed to a hypovolemia-
induced activation of the renin-angiotensin-aldosterone system (RAAS) and a compensatory 
increased uptake of sodium and water in proximal tubules. Recently, however, we discovered 
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that thiazide also has an NCC-independent effect, as NCC knockout mice with Li-NDI 
showed a clear antidiuretic response upon treatment with thiazide14.  
As urine of our thiazide-treated mice was alkalinized and thiazides are derived from carbonic 
anhydrase (CA) inhibitors15, our data indicated that the antidiuretic effect of thiazide in Li-
NDI may involve CA inhibition. CAs catalyse the hydration of carbon dioxide to form 
carbonic acid, which then rapidly dissociates to form protons and bicarbonate, and play major 
roles in pH balance regulation. Here, we show that CAs are indeed involved in lithium-
induced AQP2 downregulation and that, by inducing a tubular glomerular feedback response 
and through direct action on collecting duct cells, the CA-selective drug acetazolamide not 
only attenuates Li-NDI, but yields superior in vivo effects as compared to the presently-used 
treatment for Li-NDI. 
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Results  
The clinically used drug acetazolamide attenuates lithium-induced downregulation of AQP2 
in mpkCCD cells 
MpkCCD cells are mouse collecting duct cells showing dDAVP-dependent expression of 
endogenous AQP2 and we have shown that thiazide reduces lithium-induced downregulation 
of AQP2 in these cells, while they lack NCC expression7, 11, 14. As our previous animal studies 
suggested that thiazides reduced polyuria in our NCC knockout mice by inhibiting CAs, we 
wanted to test whether acetazolamide, a stable CA inhibitor and commonly used in patients, 
could also rescue lithium-induced AQP2 downregulation in mpkCCD cells. Indeed, whereas 
lithium again reduced the AQP2 abundance in mpkCCD cells, acetazolamide significantly 
attenuated this downregulation (Fig. 1A, B). As our data suggest that both thiazide and 
acetazolamide influence lithium-reduced AQP2 abundances through CAs, we assessed 
whether the action mechanism of acetazolamide differs from that of amiloride. If so, we 
anticipated that acetazolamide and amiloride together should attenuate the lithium-induced 
AQP2 downregulation better than cells treated with amiloride only. Indeed, immunoblotting 
revealed a significantly higher AQP2 abundance in cells treated with amiloride and 
acetazolamide as compared to amiloride only (Fig. 1C, D). Others and we discovered that 
ENaC is the main cellular entry site for lithium and that amiloride strongly reduced the 
intracellular lithium levels in mpkCCD cells11, 14. Determination of the intracellular lithium 
concentrations revealed that amiloride indeed reduced the intracellular lithium concentration 
with 87%, while this was only 30% with acetazolamide (Fig. 1E). The mean intracellular 
lithium concentration was nominally lower with amiloride/acetazolamide; however, there was 
no significant difference (p=0.23). Transcellular transport of sodium and potassium via ENaC, 
ROMK and the Na/K-ATPase is electrogenic and therefore generates a transcellular voltage 
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(Tv) over mpkCCD cell monolayers. Lithium slightly reduced the Tv, which was not further 
decreased with acetazolamide (Fig. 1F). In contrast, amiloride completely blocked the Tv in 
lithium-treated mpkCCD cells. Together, these data reveal that the CA-specific inhibitor 
acetazolamide attenuates lithium-induced downregulation of AQP2 in vitro and that its 
mechanism of action is different from that of amiloride. 
 
Acetazolamide attenuates development of lithium-induced NDI in mice 
To investigate whether acetazolamide attenuates development of Li-NDI, mice were 
maintained on lithium chow only or on lithium combined with acetazolamide or 
thiazide/amiloride for 10 days. As reported11, 16, mice treated with lithium developed severe 
polyuria and polydipsia, combined with a significantly-reduced urine osmolality (Fig. 2A-C). 
Interestingly, acetazolamide treatment induced a significant antidiuresis and increase in urine 
osmolality, which was slightly, but not significantly, better than in mice treated with 
thiazide/amiloride. Consistent with the induced antidiuresis, water intake was significantly 
reduced with the acetazolamide treatment as compared to lithium only. 
As long-term lithium treatment coincides with reduced AQP2 and increased H+-ATPase 
abundance in the kidney6, we also analyzed their abundances. Immunoblot analysis revealed 
that lithium reduced AQP2 abundance (Fig. 3A, B), which was significantly attenuated by 
both acetazolamide and thiazide/amiloride (Figs. 3A-D). With acetazolamide or 
thiazide/amiloride, however, AQP2 levels did not return to control levels. H+-ATPase levels 
were similar for all groups (Supplementary Figs. 1A-D), which is in line with the notion that 
lithium-induced collecting duct remodeling is not present after 10 days of lithium treatment in 
rodents9, 16. 
To examine segment-specific effects of the different therapies on AQP2 abundance, 
immunohistochemistry was performed. Consistent with our immunoblot data, lithium 
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treatment strongly reduced AQP2 staining, which was clearly attenuated in kidneys of mice 
treated with lithium and acetazolamide or thiazide/amiloride (Fig. 3E). Interestingly, while 
lithium abolished AQP2 expression in the entire kidney, the increased AQP2 abundance in the 
thiazide/amiloride treated group mainly localized to the inner medulla of the kidney, whereas 
in the acetazolamide treated mice, AQP2 abundance was increased along the connecting 
tubule and entire collecting duct. Consistent with our immunoblot data, 
immunohistochemistry revealed no clear changes in H+-ATPase labeling between the 
different groups (Supplementary Fig. 2).  
 
Acetazolamide shows an improved overall electrolyte balance over thiazide/amiloride.  
Some patients on thiazide/amiloride therapy have been reported to develop hyponatremia, 
hyperkalemia, metabolic acidosis and/or hypercalcemia17-20. Moreover, initiating 
thiazide/amiloride treatment in Li-NDI patients often leads to elevated blood lithium levels, 
necessitating adjustment of the lithium dose21. Therefore, to assess and compare the effect of 
acetazolamide and thiazide/amiloride on these parameters, we analyzed blood and urine for 
lithium and electrolyte levels (Table 1). Indeed, while mice treated with thiazide/amiloride 
had a reduced bodyweight and developed hyponatremia, hyperkalemia, and a metabolic 
acidosis, these parameters were not affected in acetazolamide-treated mice. Also, 
thiazide/amiloride treatment induced hypercalcemia, which was significantly reduced with 
acetazolamide, although not to control levels. Moreover, and consistent with patients, serum 
lithium concentrations were significantly increased in our thiazide/amiloride mice, but were 
unchanged in our acetazolamide mice as compared to lithium controls.  
 
The antidiuretic effect of acetazolamide coincides with a lowered GFR and a reduced 
prostaglandin E2 release 
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Paradoxically, the clear antidiuresis found in our acetazolamide group (Figs. 2A-C) coincided 
with a significantly-increased creatinine clearance (Fig. 4A). However, as the creatinine 
clearance in especially mice highly depends on both creatinine secretion and reabsorption in 
the proximal tubule, the segment mainly influenced by acetazolamide22, 23, we hypothesized 
that acetazolamide may affect proximal tubular creatinine reabsorption/secretion in our mice 
and thus that the creatinine clearance did not properly reflect the GFR. Therefore we used 
FITC-inulin to determine the GFR in an identically-performed animal experiment. While 
acetazolamide again significantly attenuated Li-NDI (not shown), the clearance of FITC-
inulin was significantly reduced with acetazolamide (Fig. 4B), indicating that acetazolamide 
reduced the GFR. Urinary prostaglandin E2 (PGE2), which extensively contributes to AQP2 
downregulation in Li-NDI24, was significantly increased in our Li-NDI mice, but was fully 
attenuated in our mice treated with lithium/acetazolamide (Fig. 4C). Moreover and consistent 
with its CA inhibitory action in proximal tubules, acetazolamide further increased urinary pH 
(Fig. 4D) and strongly reduced the abundance of NHE3 in the renal cortex as compared the 
cortex of mice treated with lithium only (Fig. 4E, F). 
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Discussion 
 
Acetazolamide is superior to thiazide/amiloride to attenuate lithium-NDI. 
Our mouse studies revealed that acetazolamide attenuates development of Li-NDI to the same 
extent as thiazide/amiloride, but, in contrast to acetazolamide, our thiazide/amiloride treated 
mice developed hyponatremia, hyperkalemia, and metabolic acidosis. In humans, 
hyponatremia is mostly a consequence of upregulated AQP2 expression by high circulating 
AVP levels. Although AVP levels are elevated in Li-NDI, this cannot explain hyponatremia 
in our thiazide/amiloride treated mice, because AQP2 is downregulated here. Instead, our data 
indicate that the hyponatremia is due to the induced natriuresis caused by thiazide and 
amiloride in a status of polyuria and polydipsia, because our Li-NDI mice were 
normonatremic and our thiazide/amiloride mice were highly natriuretic as compared to the 
other groups. Note, however, that part of the increased natriuresis must be due to an increased 
consumption of salt from the provided salt block, because food intake was not increased. The 
mice apparently drank water to satiety, because the hematocrit was not different between the 
groups (not shown). Similarly, congenital NDI patients also sometimes develop hyponatremia 
when treated with thiazide combinations25, 26.  
The observed hyperkalemia is likely due to inhibition of ENaC by amiloride, as renal 
secretion of potassium occurs only in exchange of ENaC-mediated sodium reabsorption27. 
Lithium itself can lead to metabolic acidosis28, which would even be increased with inhibition 
of bicarbonate uptake by acetazolamide, but we only found metabolic acidosis in our 
thiazide/amiloride treated mice. Whereas metabolic acidosis in our acetazolamide group may 
have been compensated by increased ventilation, metabolic acidosis in the thiazide/amiloride 
group may be secondary to the observed hyperkalemia, as mammals attenuate hyperkalemia 
at the expense of development of metabolic acidosis29.  
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Our Li-NDI mice developed hypercalcemia, which was sustained in our thiazide/amiloride 
treated mice, but not in our acetazolamide mice. Hyperparathyroidism is common with 
lithium-using patients and the occurrence of hypercalcemia in Li-NDI has been ascribed to 
inhibition of calcium-sensing receptor signaling by lithium in the parathyroid30-32. The 
corrected blood calcium levels with acetazolamide, however, may be unrelated to the 
parathyroid effect of lithium, because plasma calcium is increased by bone resorption, a 
process that involves CA2 activity in osteoclast and that is strongly inhibited by 
acetazolamide33, 34. 
Another important advantage of the use of acetazolamide over thiazide/amiloride is that 
plasma lithium concentrations remained unchanged with acetazolamide. Blood lithium is 
mainly set by the amount reabsorbed in proximal tubules, a process in which the apical NHE3 
is highly involved and which is stimulated by thiazide35, 36. Considering this, the unaltered 
blood lithium levels with acetazolamide is best explained by combinatory effects of the 
reduced NHE3 abundance in proximal tubules and the reduced GFR.  
 
Acetazolamide attenuates Li-NDI by a dual mode of action 
Our data indicate that the observed antidiuresis and reduced GFR with acetazolamide is due to 
a tubular glomerular feedback (TGF) response caused by inhibition of CAs in the proximal 
tubule37, 38. Ninety percent of renal HCO3- is reabsorbed in proximal tubules, which is strongly 
facilitated by CA4/14 (luminal/apical), CA2 (intracellular) and CA4/12 (basolateral) 
hydrating CO2 and dehydrating H2CO339. In this process, secretion of protons by NHE3 is 
important. By blocking these CA, acetazolamide prevents the intracellular generation of H+, 
which is needed for NHE3 to reabsorb filtered Na+40-43. The consequently increased tubular 
salt and water load in the proximal tubule leads to an increased fluid delivery and tubular [Cl-] 
at the macula densa, which induces a TGF response (i.e. a reduced GFR)38. Indeed, 
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acetazolamide in our Li-NDI mice led to an increased urinary pH, reduced NHE3 abundance 
and reduced GFR and are in agreement with reported data on NHE3 knockout mice38, 41, 44.   
Besides intercalated cells (see below), the increased fluid delivery to the macula densa with 
acetazolamide may also partially explain the observed lower urinary levels of PGE2, thereby 
attenuating Li-NDI. By acting on EP1/3 receptors, increased urinary PGE2 levels in Li-NDI 
reduce principal cell AQP2 expression and thus water reabsorption45. In Li-NDI, a fraction of 
the elevated urinary PGE2 levels is thought to be derived from macula densa and surrounding 
cTAL cells, which produce PGE2 to increase renin synthesis and release in response to a 
reduced fluid delivery to the TAL/hypovolemia43, 44. As such, the increased fluid delivery to 
the TAL with acetazolamide will reduce the cortical release of PGE2 and therewith Li-NDI. 
 
However, our in vitro data indicate that acetazolamide also directly protects collecting duct 
cells from lithium, but it is at present unclear whether in vivo acetazolamide acts directly on 
principal cells or indirectly via intercalated cells. Support for the first is that mpkCCD cells 
endogenously express and show proper regulation of the typical principal cell proteins, AQP2 
and ENaC. Moreover, mpkCCD cells express high CA2 mRNA levels 
(http://esbl.nhlbi.nih.gov/mpkCCD-transcriptome/), which is also expressed in principal cells 
in vivo39, 46-48. Also, the in vivo activity of ENaC, the lithium entry site of principal cells, has 
been reported to be functionally paired with CA activity, as, CA inhibition by acetazolamide 
reduced the intracellular pH and reduced ENaC activity in sweat duct cells and colon49, 50. 
However, mpkCCD cells may not fully represent principal cells and, as intercalated cells 
express abundant levels of CAs 2, 4, 12, and 1539, acetazolamide may increase principal cell 
AQP2 expression and water uptake indirectly by inhibiting ACs in intercalated cells. Indeed, 
long-term lithium treatment leads to metabolic acidosis, which underlies the increased number 
of α-intercalated cells11, 51 and, as lithium inhibits intercalated cell H+-ATPase and H+/K+-
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ATPase activity52, 53, it has been suggested that acidosis-induced proliferation of α-
intercalated cells may contribute to Li-NDI16. It is unlikely, however, that attenuation of Li-
NDI in our mice is due to direct action of acetazolamide on α-intercalated cells or collecting 
duct remodeling for several reasons: At first, acetazolamide increases the number of α-
intercalated cells in rodents, as it causes acidosis itself54, 55. Secondly and consistent with the 
unchanged H+-ATPase expression in our mice, collecting duct remodeling is not observed 
with 10 days of lithium treatment, but only starts at about 4 weeks of treatment9, 56. 
An effect of acetazolamide on β-intercalated cells, however, may be more likely. While 
lithium treatment did not reduce the number of these cells57, exciting recent studies revealed 
the existence of extensive cross-talk between β-intercalated and principal cells in the 
regulating collecting duct function58-61. While Eladari et al elegantly showed that in rodents, 
the sodium-dependent chloride bicarbonate exchanger (NDCBE/SLC4a8) and chloride 
bicarbonate exchanger protein pendrin allow for NaCl reabsorption through β-intercalated 
cells, chloride permeation through pendrin also appeared necessary for ENaC mediated 
sodium reabsorption and expression62. Also, in mice lacking functional intercalated cell-
specific H+-ATPase, the observed natriuresis and aquaresis was due to dysfunctional and 
lower abundances of ENaC and pendrin/NDCBE, and reduced AQP2 levels, respectively60. 
The authors further showed that the lack/inhibition of β-intercalated cells H+-ATPase led, via 
flow-stimulated luminal ATP release, to autocrine and paracrine release of PGE2, which 
reduced the cortical and medullary ENaC activity and AQP2 abundance. Importantly, 
thiazides inhibited NCC-independent NaCl reabsorption through NDCBE/pendrin59 and 
acetazolamide reduced pendrin abundance63, drugs we showed to attenuate Li-induced 
downregulation of AQP2 and Li-NDI through a similar mechanism. As such, the attenuated 
Li-NDI with acetazolamide, which was given during the entire lithium treatment, may be due 
to an impaired functioning of pendrin, resulting in increased ATP/PGE2 release, reduced 
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ENaC activity in principal cells, and thus reduced influx of lithium from pro-urine. The 
finding that acetazolamide is beneficial chiefly in the cortical segments that contain 
intercalated cells is consistent with the possibility that intercalated cell CAs could be 
involved. A prime candidate here is CA12, as it is highly sensitive to acetazolamide and 
patients with reduced CA12 activity have a preponderance to hyponatremic dehydration64. 
Whether one of these mechanisms underlies the beneficial effect of acetazolamide in Li-NDI 
remains to be studied. 
 
Taken together, we have shown that CAs activity contributes to Li-NDI development, that 
acetazolamide attenuates lithium-induced NDI by inducing a TGF response and through a 
direct action on the collecting duct, and that acetazolamide attenuates Li-NDI development 
similar to thiazide/amiloride but with less side effects. 
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Concise methods 
Cell culture  
MpkCCD cells were cultured as described65. Cells were seeded at a density of 1.5x105 
cells/cm2 on semi-permeable filters (Transwell, 0.4 m pore size, Corning Costar, Cambridge, 
MA) and cultured for 8 days. Unless stated otherwise, the cells were exposed to 1 nM of 
dDAVP at the basolateral side for the last 96 hr, to induce AQP2 expression. Lithium and 
compounds were administered as indicated. At the end of the experiment, transcellular 
electrical resistance and voltage were measured using a Millicell-ERS meter (Millipore corp., 
Bedford, MA, USA). On day 8, cells were harvested and lysed in Laemmli buffer for western 
blotting or stored in Trizol reagent (Invitrogen, Carlsbad, CA) at -80°C for RNA-isolation.  
 
Lithium assays 
Determination of intracellular lithium concentrations was done as described11. Shortly, 
mpkCCDcl4 cells were grown on 4.7 cm2 filters. To determine the extent of lithium 
contamination from the extracellular side, fluorescein isothiocyanate (FITC) dextran was 
added to the lithium-containing medium to a final concentration of 10 M just before 
harvesting, after which the medium was mixed. Then, the filters were washed three times with 
iso-osmotic sucrose (pH 7.3) at 4°C and cells were lysed by sonication in 1 ml milli-Q water. 
Of 800 l sample, the amount of lithium was determined by flame photometry, from which 
the total amount of lithium in the sample was calculated.  
Of 100 l sample, the amount of FITC-dextran was measured using spectrofluorophotometry 
(Shimadzu RF-5301, Japan) at 492 nM (excitation) and 518 nm (emission) wavelengths. By 
comparing the obtained values with a two-fold FITC-dextran dilution series, the FITC-dextran 
concentration in each sample was determined, from which the extent of extracellular lithium 
contamination was calculated. This was subtracted from the total amount to obtain the 
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intracellular lithium amount. With the used FITC-dextran concentration, a contamination 
above 1:5000 would be detected. To correct for differences in cellular yield, the intracellular 
lithium amounts were normalized for the protein amount in each sample, which was 
determined using the Biorad Protein Assay (München, Germany).  
 
Experimental animals 
8-10 weeks old female C57Bl6/JOlaHsd mice (Harlan Laboratories, The Netherlands) were 
maintained in a temperature-controlled room with lights on 8.00 AM and PM. They received 
normal diet (ssniff R/M-H V1534, ssniff Spezialdiaten GmbH, Soest, Germany) with 
additions (see below) and water ad libitum for 10 days. For the experiments, mice were 
divided into four groups (n = 8), which were treated as follows: Group 1: Control mice given 
a normal diet; Group 2: Normal diet with 40 mmol LiCl /kg of dry food.66 Group 3: diet of 
group 2 with 200 mg amiloride11 and 350 mg hydrochlorothiazide per kg dry food36. Group 4: 
diet of group 2 with 180 mg acetazolamide /kg dry food.67 LiCl, amiloride, 
hydrochlorothiazide and acetazolamide were solubilized in water and mixed with the chow 
after which it was dried. All mice had free access to water, food, and a sodium-chloride block. 
For the last 48 hr of the experiment, mice were housed in metabolic cages to measure water 
intake and urine output during the last 24 hr. Mice were anesthetized with isofluorothane after 
which their blood was removed by orbita extraction. Then, mice were killed by cervical 
dislocation and the kidneys rapidly removed. One kidney was processed for 
immunohistochemistry, whereas the other kidney was used for immunoblotting, both as 
described below. For immunoblotting, the tissue was homogenized using a Polytron 
homogenizer (VWR international, Amsterdam, The Netherlands) in 1 ml of ice-cold 
homogenization buffer A (20 mM Tris, 5 mM MgCl2, 5 mM Na2HPO4, 1 mM EDTA, 80 mM 
sucrose and protease inhibitors (1 mM PMSF, 5 µg/ml pepstatin A, 5 µg/ml leupeptin, and 5 
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µg/ml a-protinin) and cleared from nuclei and unbroken cells by centrifugation at 4000 x g for 
15 min and diluted in Laemmli buffer to a final protein concentration of 1 μg/μl. 
 
Determination of glomerular filtration rate using FITC-inulin. 
To determine the glomerular filtration rate via the FITC-inulin clearance method 68, 69 we used 
mice as described above and these mice were also treated as before (n=8/group). Four days 
after the start of the diet, minipumps (Model 2001, Alzet) containing 3% FITC inulin were 
subcutaneously implanted in the isofluorane-anesthetized mice. At treatment days 9 and 10, 
mice were housed in metabolic cages and 24 hr urine was collected in amber tubes at day 10. 
During this 24 hr, metabolic cages and urine collection tubes were covered with aluminium 
foil to prevent exposure to light. Traces of left FITC-inulin urine in metabolic cages were 
added to the collected urine by washing the cage with 5 mL of 500 mmol HEPES buffer. On 
day 10, mice were anesthetized with isofluorane, blood was collected by retro-orbital bleeding 
and mice were killed by cervical dislocation. Urine fluorescence was determined using a 
Cytofluor II fluorescence multi-well plate reader (PerSeptive Biosystems, Framingham, MA, 
USA) with 485 nm excitation and 538 nm emission. The excretion rate of inulin (24 hr 
urinary fluorescence counts/plasma fluorescence counts per ml) was taken as the GFR. 
 
Blood and urine analysis 
Whole blood was analyzed immediately for sodium, potassium, hematocrit, and pH using the 
EG7+ cartridge and the I-Stat Clinical Analyzer (Abbott BV, Hoofddorp, The Netherlands). 
The remaining blood was collected in a BD microtainer SST tube (REF #365968, Becton 
Dickinson BV, Breda, The Netherlands) for serum and centrifuged at 10.000 x g for 3 min to 
sediment the red blood cells. Serum and urine samples were analyzed for osmolality using an 
osmometer (Fiske, Needham Heights, MA), and electrolyte concentrations were measured on 
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a Synchron CX5 analyzer (Beckman Coulter, Brea, CA), following the manufacturer's 
protocols. Urine PGE2 levels were determined by measuring stable PGE2 metabolite (PGEM) 
after chemical derivation of PGE2 and its primary metabolites, 13,14-dihydro-15-keto PGE2 
and 13,14-dihydro-15-keto PGA2, to the single PGEM compound. PGEM concentrations 
were determined with the prostaglandin E metabolite EIA kit (Cayman Chemical Company, 
Ann Arbor, MI, USA) according to the manufacturer’s instructions. 
 
Immunoblotting 
MpkCCD cells from 1.13 cm2 filters were lysed in 200 l Laemmli buffer and sonicated. 
MpkCCD lysate and 5-10 μg kidney material in Laemmli were denatured for 30 min at 37°C. 
Protein concentration was determined using the BioRad protein assay (Bio-Rad Laboratories 
GmbH, München, Germany), according to manufacturer’s instructions. SDS-PAGE, blotting 
and blocking of the PVDF membranes were done as described70. Membranes were incubated 
for 16 hr at 4C with 1:2000 affinity-purified rabbit pre-c-tail AQP2 antibody recognizing aa 
236-255,71 in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% non-fat dried 
milk. In an identical way, other blots were incubated with a rabbit CA12 antibody (kind gift 
from Prof. William S. Sly, Saint Louis University School of Medicine, St. Louis, MO, USA) 
and a rabbit CA2 antibody (Abcam, Cambridge, UK). After washing in TBS-T, all blots were 
incubated for 1 hr with 1:5000-diluted goat anti-rabbit IgG’s (Sigma, St. Louis, MO) as 
secondary antibody coupled to horseradish peroxidase. Proteins were visualized using 
enhanced chemiluminescence (ECL, Pierce, Rockford, IL). Densitrometric analyses were 
performed using Biorad quantification equipment (Bio-Rad 690c densitometer, Chemidoc 
XRS) and software (QuantityOne, Bio-Rad Laboratories GmbH, München, Germany). Equal 
loading of the samples was confirmed by staining of the blots with Coomassie blue.  
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Immunohistochemistry 
Kidneys were fixed by immersion for 24h in 4% paraformaldehyde in 0.1M phosphate buffer 
at 4°C, embedded in paraffin and cut into 3-4 μm-thick sections. After de-paraffinization, 
sections were placed into a microwave oven and heated for 10 minutes at 98°C in 0.01 M 
sodium-citrate buffer (pH 6.0) for antigen retrieval. Subsequently, sections were incubated 
overnight at 4°C with 1:80000-diluted rabbit polyclonal AQP2 antibodies or 1:2000-diluted 
rabbit polyclonal H+-ATPase antibodies as described72, 73. The bound primary antibodies were 
revealed with Cy3-coupled goat-anti rabbit IgG (Jackson ImmunoResearch Laboratories, PA, 
USA). To check for unspecific binding of primary or secondary antibodies, incubations with 
non immune sera or without any primary antibodies were performed. All control experiments 
were negative. Cryosections were studied by epifluorescence using a Leica microscope 
(Wetzlar, Germany). Connecting tubules and cortical collecting ducts were distinguished 
based on their specific localization in the cortical labyrinth and the medullary rays, 
respectively. Images were acquired with a charge-coupled device camera. For overviews, 
single images were taken with the automated scanning mode of the microscope and 
afterwards stitched using the Leica Application Suite. Digital images were processed 
electronically with Adobe Photoshop and Microsoft Powerpoint software. Adjustments for 
brightness and contrast were kept constant for each kidney section.  
 
Statistics  
One-way ANOVA with Bonferroni correction was applied. A p value of less than 0.05 was 
considered significant. Data are presented as mean and standard error of the mean (SEM). 
 
Study approval 
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All animal studies (DEC nr 2011-010) were approved by the Animal Ethical Committee of 
the Radboud University Medical Center. 
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Figure legends 
 
Figure 1. Acetazolamide reduces lithium-induced downregulation of AQP2 abundance 
in mpkCCD cells.  
Native mpkCCD cells were grown to confluence for 4 days and subsequently exposed to 1 
nM dDAVP for another 4 days. During the last 2 days, cells were incubated in the absence 
(Ctr) or presence of lithium only (Li+) or with lithium and 100 μM acetazolamide (Acz), 10 
μM amiloride (Am), 100 μM hydrochlorothiazide and amiloride (T+Am) or amiloride and 
acetazolamide (Am+Acz). At the basolateral and apical side, final concentrations of 1 and 10 
mM lithium were used, respectively. Following measurements of transcellular voltage (F), 
cells were lysed and subjected to AQP2 immunoblotting (A, C). Molecular masses (in kDa) 
are indicated. The signals for non-glycosylated (29 kDa) and complex-glycosylated (40-45 
kDa) AQP2 were densitometrically quantified (B, D). Mean values +/- SEM of normalized 
AQP2 abundance are given relative to control. (E) Intracellular lithium concentrations were 
determined, which were corrected for contamination with extracellular lithium and 
normalized for the amount of protein ([Li+] +/- SEM in pmol/μg protein). Data from 3 
independent experiments, one way ANOVA, Bonferroni's Multiple Comparison Test, 
*p<0.05. 
 
Figure 2. The antidiuretic effect of thiazide/amiloride and acetazolamide treatment on 
lithium-treated mice. Urine volume (A), water intake (B) and urine osmolality (C) of 
untreated mice (CTR) or of mice treated for 10 days with lithium (Li+) or in combination with 
thiazide/amiloride (T+Am) or acetazolamide (Acz). During the last 48 hr mice were housed in 
metabolic cages and during the last 24 hr water intake was measured and urine was collected 
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to determine urine volume and osmolality. n=8 mice/group, one way ANOVA, Bonferroni's 
Multiple Comparison Test, *p<0.05. 
 
Figure 3. Thiazide/amiloride and acetazolamide reduce lithium-induced downregulation 
of AQP2 in lithium-NDI mice. (A-D) Immunoblot and corresponding densitometric analysis 
of AQP2 of mouse kidneys that are untreated (Ctr), treated with lithium only (Li+) or with 
lithium together with acetazolamide (Acz) or thiazide/amiloride (T+Am). The signals for 
AQP2 densitometrically quantified (B and D). Mean values +/- SEM of normalized AQP2 
abundance is given relative to control. Asterisks indicate significant differences (p<0.05) from 
controls. Equal loading of the samples was confirmed by staining of the blots with coomassie 
blue (Cm). One way ANOVA, Bonferroni's Multiple Comparison Test, *p<0.05. (E) Paraffin 
sections of immersion-fixed kidneys from control (Ctr; A, E, I), lithium-treated (Li+; B, F, J), 
lithium/amiloride/thiazide-treated (Li+ + T + Am; C, G, K), and lithium/acetazolamide-treated 
mice (Li+ + Acz; D, H, L) were incubated with a rabbit polyclonal AQP2 antibody followed 
by a Cy3-coupled goat-anti rabbit IgG. Overviews (A-D) and high magnifications of 
representative connecting tubules (CNT; E-H), and cortical collecting ducts (CCD; I-L).  
 
Figure 4. The effect of acetazolamide on urinary pH, NHE3 abundance, glomerular 
filtration rate and prostaglandin-E2 release. Mice were treated for 10 days with control 
diet (Ctr) or diet containing lithium (Li+) only or lithium in combination with acetazolamide 
(Acz). During the last 48 hr, mice were housed in metabolic cages and during the last 24 hr 
urine was collected to determine creatinine clearance (A), PGE2 levels (C) and urinary pH 
(D). At day 10, mice were sacrificed and blood and kidneys were isolated, enabling the 
analysis of renal NHE3 abundance (E, F). In (E) the arrow indicates the ~85kDa band of 
NHE3. To measure GFR, using FITC-inulin, the above-mentioned experiment was repeated, 
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however at day 4 osmotic minipumps containing FITC-inulin, were implanted and at day 10 
FITC-inulin levels were measured in 24 hr urine and serum (B). n=8 mice/group, one way 
ANOVA, Bonferroni's Multiple Comparison Test, *p<0.05. 
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Table 1. Metabolic parameters of mice treated for 10 days with standard chow only (Ctr) or together with 
lithium (Li+), lithium + thiazide + amiloride (Li+ + T + Am), or lithium + acetazolamide (Li+ + Acz). 
 
Li+, lithium; T, thiazide; Am, amiloride; Acz, acetazolamide. 
Values are means ± s.e.m. 
* P<0.05 compared to control treatment 
**  P<0.05 compared to lithium treatment 
† P<0.05 compared to lithium/thiazide/amiloride treatment 
/  Below detection limit 
 
 
 
 
 Ctr Li+ Li+ + Am + T Li+ + Acz 
Serum Osmolality (mOsm/kg) 320 ± 1 319 ± 1 311 ± 0.5** 321 ± 3 † 
Serum Sodium (mmol/l) 150 ± 0.3 149 ± 0.4 139 ± 0.8** 150 ± 0.5† 
Serum Potassium (mmol/l) 5.3 ± 0.1 5.6 ± 0.2 7.6 ± 0.5** 5.4 ± 0.2† 
Serum Lithium (mmol/l) / 0.63 ± 0.04* 2.11 ± 0.12** 0.69 ± 0.04† 
Serum Creatinine (mg/dl) 0.08 ± 0.01 0.09 ± 0.00 0.06 ± 0.01** 0.04 ± 0.01**/† 
Blood Ionized Calcium (mmol/l) 1.24 ± 0.00 1.32 ± 0.01* 1.34 ± 0.01 1.27 ± 0.01**/† 
Blood pH  7.34 ± 0.01 7.32 ± 0.01 7.24 ± 0.02** 7.35 ± 0.02† 
     
Urine sodium (mmol/l) 352 ± 40 46 ± 6* 484 ± 68 ** 112 ± 12† 
Urine potassium (mmol/l) 870 ± 83 131 ± 15* 154 ± 19 271 ± 31**/† 
Urine lithium (mmol/l) / 20 ± 3* 24 ± 3 38 ± 8 
Urine Creatinine (mg/dl) 70 ± 7 10 ± 1* 14 ± 2 18 ± 2** 
     
Total sodium excretion (mmol/24 hr) 0.17 ± 0.02 0.16 ± 0.01 1.26 ± 0.12** 0.22 ± 0.02† 
Total potassium excretion (mmol/24 
hr) 0.42 ± 0.05 0.55 ± 0.02* 0.40 ± 0.03** 0.54 ± 0.05 
Total lithium excretion (mmol/24 hr) / 84 ± 3* 64 ± 6 72 ± 11 
     
Bodyweight (g) 18.9 ± 0.4  18.0 ± 0.2* 16.0 ± 0.5** 17.4 ± 0.4† 
Food Intake (mg/g/24 hr)  214 ± 8 198 ± 10 188 ± 5 228 ± 5**/† 
Feces Production (mg/g/24 hr) 111 ± 7 98 ± 8 82 ± 2 123 ± 9† 
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